ACRS
Aclaris Therapeutics, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
-14/100
Last price
3.70
▼ 0.57 (13.35%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
4.27
Day high
4.24
Day low
3.65
Volume
3.53M
Market cap
$544.64M
P/E (TTM)
—
52W range
1.74 – 6.60
Trailing performance
Returnvs SPY
1W
-29.92%
-31.9%
1M
-40.03%
-41.2%
3M
-32.85%
-37.4%
6M
-1.33%
-19.5%
YTD
+22.92%
+8.7%
1Y
+98.92%
+82.5%
3Y
-45.99%
-128.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ACRS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-157.77K
Net selling
Buy transactions
8
142.23K shares
Sell transactions
1
300.00K shares
Net transactions
+9
Buys less sells
Sell : buy shares
2.1 : 1
Mixed
Insider-held shares
3.21M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 31, 26 | KOLBECK ROLAND WILHELM Officer |
— | 36.38K | — | Direct |
| Jun 5, 26 | MEHRA ANAND M.D. Director |
— | 11.58K | — | Direct |
| Jun 5, 26 | MILANO VINCENT J Director |
— | 11.58K | — | Direct |
| Jun 5, 26 | SCHIFF ANDREW N Director |
— | 11.58K | — | Direct |
| Jun 5, 26 | GOWEN MAXINE Director |
— | 11.58K | — | Direct |
| Jun 5, 26 | MOLINEAUX CHRISTOPHER P Director |
— | 11.58K | — | Direct |
| Jun 5, 26 | HUMPHRIES WILLIAM DOUGLAS Director |
— | 11.58K | — | Direct |
| May 1, 26 | HALL JESSE WAYNE M.D. Officer |
— | 36.38K | — | Direct |
| Apr 23, 26 | LEONARD BRADEN MICHAEL Beneficial Owner of more than 10% of a Class of Security |
SELL | 300.00K | $1.36M | Indirect |
| Feb 27, 26 | BALTHASER KEVIN J Chief Financial Officer |
— | 2.38K | — | Direct |
| Feb 3, 26 | WALKER NEAL Chief Executive Officer |
— | 63.48K | — | Direct |
| Feb 3, 26 | LOEROP JAMES Officer |
— | 20.88K | — | Direct |
| Feb 3, 26 | BALTHASER KEVIN J Chief Financial Officer |
— | 22.02K | — | Direct |
| Feb 3, 26 | DAVIS HUGH M. President |
— | 18.68K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BALTHASER KEVIN J |
Chief Financial Officer | 187.45K | Conversion of Exercise of derivative security |
DAVIS HUGH M. |
President | 45.42K | Conversion of Exercise of derivative security |
HUMPHRIES WILLIAM DOUGLAS |
Director | 45.10K | Conversion of Exercise of derivative security |
LEONARD BRADEN MICHAEL |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
LOEROP JAMES |
Officer | 192.26K | Conversion of Exercise of derivative security |
MEHRA ANAND M.D. |
Director | 726.40K | Conversion of Exercise of derivative security |
MOLINEAUX CHRISTOPHER P |
Director | 69.54K | Conversion of Exercise of derivative security |
MONAHAN JOSEPH B |
Officer | 265.86K | Conversion of Exercise of derivative security |
SCHIFF ANDREW N |
Director | 460.00K | Conversion of Exercise of derivative security |
WALKER NEAL |
Chief Executive Officer | 1.54M | Conversion of Exercise of derivative security |
Fundamentals
Market cap$544.64M
Enterprise value$454.93M
Revenue (TTM)$8.22M
Gross profit$-62.27M
EBITDA$-85.53M
Net income$-75.74M
EPS (TTM)$-0.58
Free cash flow$-41.97M
Total cash$91.56M
Total debt$1.85M
Book value / share$0.89
Shares outstanding147.20M
Float101.17M
Short % of float12.40%
Dividend yield0.00%
Beta (5Y)0.88
Valuation & profitability ratios
Trailing P/E—
Forward P/E-4.70
PEG ratio—
Price / sales—
Price / book4.15
EV / revenue55.35
EV / EBITDA-5.32
Gross margin0.00%
Operating margin-1469.49%
Profit margin0.00%
Return on equity-59.10%
Return on assets-28.98%
Debt / equity1.49
Current ratio3.46
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $7.83M | $18.72M | $31.25M | $29.75M | — | -58.2% |
| Operating revenue | $7.83M | $18.72M | $31.25M | $29.50M | — | -58.2% |
| Cost of revenue | $7.28M | $15.46M | $18.08M | $11.96M | — | -52.9% |
| Gross profit | $542.00K | $3.26M | $13.17M | $17.79M | — | -83.4% |
| Research & development | $52.65M | $33.59M | $98.38M | $77.81M | — | +56.7% |
| Selling, general & admin | $21.97M | $22.20M | $31.10M | $25.13M | — | -1.0% |
| Total operating expense | $74.62M | $55.79M | $129.48M | $102.95M | — | +33.7% |
| Operating income | -$74.08M | -$52.53M | -$116.31M | -$85.15M | — | -41.0% |
| Net interest income | $7.64M | $7.95M | — | — | — | -4.0% |
| Pre-tax income | -$64.92M | -$132.06M | -$88.85M | -$86.91M | — | +50.8% |
| Tax provision | — | $0 | -$367.00K | $0 | $0 | — |
| Net income | -$64.92M | -$132.06M | -$88.48M | -$86.91M | — | +50.8% |
| Net income to common | -$64.92M | -$132.06M | -$88.48M | -$86.91M | — | +50.8% |
| Basic EPS | -0.53 | -1.71 | -1.27 | -1.33 | — | +69.0% |
| Diluted EPS | -0.53 | -1.71 | -1.27 | -1.33 | — | +69.0% |
| EBIT | -$74.08M | -$52.53M | -$116.31M | -$85.15M | — | -41.0% |
| EBITDA | -$73.62M | -$51.72M | -$115.45M | -$84.36M | — | -42.3% |
| Basic shares | 122.56M | 77.30M | 69.81M | 65.21M | — | +58.6% |
| Diluted shares | 122.56M | 77.30M | 69.81M | 65.21M | — | +58.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $19.96M | $24.57M | $39.88M | $45.28M | — | -18.8% |
| Cash & short-term investments | $90.75M | $113.59M | $119.11M | $217.57M | — | -20.1% |
| Accounts receivable | — | $318.00K | $298.00K | $484.00K | $623.00K | — |
| Total current assets | $96.32M | $125.95M | $128.86M | $231.55M | — | -23.5% |
| Property, plant & equipment | $761.00K | $1.01M | $1.62M | $1.10M | — | -24.5% |
| Goodwill & intangibles | — | — | $269.00K | $6.97M | $7.05M | — |
| Total assets | $160.46M | $220.33M | $197.41M | $254.60M | — | -27.2% |
| Total current liabilities | $28.64M | $31.60M | $30.95M | $21.94M | — | -9.3% |
| Total debt | — | — | $426.00K | $684.00K | $693.00K | — |
| Total liabilities | $57.38M | $64.77M | $40.23M | $56.98M | — | -11.4% |
| Retained earnings | -$967.78M | -$902.86M | -$770.80M | -$682.32M | — | -7.2% |
| Shareholder equity | $103.08M | $155.55M | $157.18M | $197.62M | — | -33.7% |
| Working capital | $67.67M | $94.36M | $97.90M | $209.61M | — | -28.3% |
| Net tangible assets | $103.08M | $155.55M | $157.18M | $190.65M | — | -33.7% |
| Shares issued | 120.50M | 107.85M | 70.89M | 66.69M | — | +11.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$64.92M | -$132.06M | -$88.48M | -$86.91M | +50.8% |
| Depreciation & amortisation | $454.00K | $807.00K | $863.00K | $797.00K | -43.7% |
| Stock-based compensation | $12.38M | $10.86M | $20.54M | $15.04M | +14.1% |
| Change in working capital | $2.67M | $10.92M | $9.39M | -$1.20M | -75.5% |
| Operating cash flow | -$47.11M | -$20.07M | -$78.33M | -$67.57M | -134.7% |
| Capital expenditure | -$111.00K | -$35.93M | -$1.31M | -$605.00K | +99.7% |
| Investing cash flow | $48.37M | -$69.77M | $46.22M | $12.63M | +169.3% |
| Financing cash flow | -$5.86M | $74.54M | $26.71M | $72.87M | -107.9% |
| Free cash flow | -$47.22M | -$56.01M | -$79.63M | -$68.17M | +15.7% |
| End cash position | $19.96M | $24.57M | $39.88M | $45.28M | -18.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $1.63M | $2.00M | $1.29M | $3.30M | $1.78M | -18.4% |
| Operating revenue | $1.63M | $2.00M | $1.29M | $3.30M | $1.78M | -18.4% |
| Cost of revenue | $1.45M | $1.79M | $1.47M | $2.45M | $1.85M | -18.7% |
| Gross profit | $176.00K | $208.00K | -$174.00K | $850.00K | -$73.00K | -15.4% |
| Research & development | $18.07M | $15.66M | $16.58M | $13.03M | $11.45M | +15.4% |
| Selling, general & admin | $6.05M | $6.74M | $5.58M | $4.87M | $5.39M | -10.3% |
| Total operating expense | $24.11M | $22.40M | $22.16M | $17.90M | $16.84M | +7.7% |
| Operating income | -$23.94M | -$22.19M | -$22.33M | -$17.05M | -$16.91M | -7.9% |
| Net interest income | $1.76M | $1.51M | $1.63M | $1.82M | $2.02M | +16.3% |
| Pre-tax income | -$21.50M | -$19.82M | -$19.80M | -$14.61M | -$15.43M | -8.5% |
| Net income | -$21.50M | -$19.82M | -$19.80M | -$14.61M | -$15.43M | -8.5% |
| Net income to common | -$21.50M | -$19.82M | -$19.80M | -$14.61M | -$15.43M | -8.5% |
| Basic EPS | -0.15 | -0.15 | -0.16 | -0.12 | -0.13 | 0.0% |
| Diluted EPS | -0.15 | -0.15 | -0.16 | -0.12 | -0.13 | 0.0% |
| EBIT | -$23.94M | -$22.19M | -$22.33M | -$17.05M | -$16.91M | -7.9% |
| EBITDA | -$23.83M | -$22.09M | -$22.23M | -$16.94M | -$16.79M | -7.9% |
| Basic shares | 142.74M | 128.81M | 122.66M | 122.62M | 122.58M | +10.8% |
| Diluted shares | 142.74M | 128.81M | 122.66M | 122.62M | 122.58M | +10.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $19.17M | $28.66M | $19.96M | $25.26M | $25.40M | — | -33.1% |
| Cash & short-term investments | $91.56M | $105.42M | $90.75M | $95.91M | $99.81M | — | -13.1% |
| Accounts receivable | — | — | — | $4.68M | $194.00K | $250.00K | — |
| Total current assets | $97.77M | $110.23M | $96.32M | $100.59M | $104.20M | — | -11.3% |
| Property, plant & equipment | $664.00K | $750.00K | $761.00K | $811.00K | $868.00K | — | -11.5% |
| Total assets | $179.69M | $198.72M | $160.46M | $175.53M | $189.15M | — | -9.6% |
| Total current liabilities | $28.24M | $27.37M | $28.64M | $25.63M | $26.84M | — | +3.2% |
| Total liabilities | $55.11M | $55.07M | $57.38M | $55.43M | $57.41M | — | +0.1% |
| Retained earnings | -$1.01B | -$987.61M | -$967.78M | -$947.99M | -$933.38M | — | -2.2% |
| Shareholder equity | $124.58M | $143.65M | $103.08M | $120.10M | $131.74M | — | -13.3% |
| Working capital | $69.52M | $82.86M | $67.67M | $74.96M | $77.36M | — | -16.1% |
| Net tangible assets | $124.58M | $143.65M | $103.08M | $120.10M | $131.74M | — | -13.3% |
| Shares issued | 139.82M | 139.65M | 120.50M | 108.34M | 108.33M | — | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$21.50M | -$19.82M | -$19.80M | -$14.61M | -$15.43M | -8.5% |
| Depreciation & amortisation | $107.00K | $102.00K | $102.00K | $110.00K | $114.00K | +4.9% |
| Stock-based compensation | $2.67M | $3.20M | $2.93M | $2.86M | $3.06M | -16.4% |
| Change in working capital | -$1.42M | -$1.63M | $3.24M | $612.00K | $759.00K | +12.6% |
| Operating cash flow | -$19.85M | -$18.15M | -$13.13M | -$10.93M | -$9.99M | -9.4% |
| Capital expenditure | -$58.00K | -$13.00K | -$24.00K | -$23.00K | -$21.00K | -346.2% |
| Investing cash flow | $10.26M | -$30.93M | $10.37M | $13.83M | $5.05M | +133.2% |
| Financing cash flow | $91.00K | $57.78M | -$2.53M | -$3.04M | -$9.00K | -99.8% |
| Free cash flow | -$19.91M | -$18.16M | -$13.15M | -$10.96M | -$9.18M | -9.6% |
| End cash position | $19.17M | $28.66M | $19.96M | $25.26M | $25.40M | -33.1% |
Options analytics
Put / call volume
0.84
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
1.00
-73.0% from spot
ATM implied vol
50.0%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
164
Contracts, this expiry
Put volume
137
Contracts, this expiry
Heaviest call OI
1.00
0 contracts
Heaviest put OI
3.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.16 | -0.15 | +6.3% |
| Mar 2026 | -0.16 | -0.15 | +3.7% |
| Dec 2025 | -0.14 | -0.16 | -17.1% |
| Sep 2025 | -0.14 | -0.12 | +14.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.17 | 10 | $1.30M | -60.7% |
| Next quarter | -0.17 | 10 | $1.43M | +10.7% |
| Current year | -0.64 | 10 | $6.34M | -19.0% |
| Next year | -0.79 | 11 | $5.34M | -15.8% |
Analyst targets & ownership
Mean target$10.18
High target$16.00
Low target$4.00
Implied upside175.18%
Analyst count11
ConsensusSTRONG BUY
Strong buy / Buy1 / 10
Hold1
Sell / Strong sell0 / 0
Held by insiders2.18%
Held by institutions84.00%
Institutions holding199
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
4.85
-23.76% from price
SMA 20
5.18
-28.56% from price
SMA 50
5.66
-34.58% from price
SMA 100
5.28
-29.97% from price
SMA 200
4.46
-17.00% from price
EMA 12
4.80
-22.88% from price
EMA 26
5.20
-28.88% from price
EMA 50
5.37
-31.14% from price
RSI (14)
24.2
Oversold
MACD (12,26,9)
-0.41
Hist -0.16
ATR (14)
0.39
10.66% of price
Realised vol 30D
81.9%
Annualised
Bollinger upper
6.24
20, 2σ
Bollinger lower
4.12
20, 2σ
50 / 200 cross
Golden
5.66 vs 4.46
Trend bias
Below 200
-17.00%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.54
Less volatile than market
Correlation to SPY
0.07
Largely independent
Realised vol 30D
81.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-43.4%
Peak to trough
Max drawdown 5Y
-96.5%
Peak to trough
ATR 14
0.39
10.66% of price
Beta (reported)
0.88
5Y monthly, from filing
Short interest
Shares short
16.08M
Prior 14.71M
Change vs prior
+9.3%
Shorts adding
% of float
12.40%
Elevated
% of shares out
10.92%
Against total outstanding
Days to cover
7.5
Crowded exit
Float
101.17M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 1, 26 | Canaccord Genuity | INITIATED | — | Buy |
| Jun 2, 26 | LifeSci Capital | INITIATED | — | Outperform |
| May 5, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| May 5, 26 | Guggenheim | INITIATED | — | Buy |
| Apr 29, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Apr 16, 26 | Oppenheimer | INITIATED | — | Outperform |
| Mar 31, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Mar 19, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jan 28, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jan 21, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Oct 20, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 25, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Offering Registrations
S-3ASR · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-06-04
Corporate Changes & Voting Matters
8-K · 2026-05-07
Corporate Changes & Voting Matters
8-K · 2026-04-28
Proxy Statements
DEF 14A · 2026-04-23
Corporate Changes & Voting Matters
8-K · 2026-03-11
Corporate Changes & Voting Matters
8-K · 2026-03-10
Periodic Financial Reports
10-K · 2026-02-26
Headlines
Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?
Zacks · 22d ago
Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
GlobeNewswire · 34d ago
Canaccord Genuity Initiates Aclaris Therapeutics at Buy With $10 Price Target
MT Newswires · 36d ago
Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade
Zacks · 58d ago
Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)
GlobeNewswire · 61d ago
Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)
GlobeNewswire · 61d ago
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
Zacks · 62d ago
Aclaris: Q2 Earnings Snapshot
Associated Press · 62d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.